Robert Hegele (0000-0003-2861-5325)

Personal information

Biography

Robert A. Hegele MD FRCPC Cert Endo FACP FCAHS FAHA
Jacob J. Wolfe Distinguished Medical Research Chair
Martha Blackburn Chair in Cardiovascular Research
Distinguished University Professor of Medicine and Biochemistry
Scientist, Robarts Research Institute
University of Western Ontario

Rob Hegele cares for >2800 patients in his lipid clinic at University Hospital in London, Ontario. His laboratory discovered the causal genes for >20 human diseases and also developed the world’s first targeted next-generation sequencing panel for dyslipidemias. He is also known for characterizing the polygenic basis of human lipid disorders. He was among the first in the world to use five medications that are now routinely prescribed to treat dyslipidemia or diabetes. He has published 960 papers with >88,000 citations on Google Scholar and is in the top 1% of highly cited scientists in the world. The website Expertscape.com in 2023 ranked him #1 globally in the area of “hypertriglyceridemia” and #2 for “disorders of lipid metabolism”. He received the 2019 American Heart Association Lyman Duff Award, the 2020 FH Foundation Pioneer Award, and 2024 US National Lipid Association Virgil Brown Distinguished Achievement Award. He has co-authored many clinical practice guidelines for cholesterol, blood pressure, and diabetes. He has trained numerous physicians, medical students, and graduate students.

Activities

Collapse all

University of Western Ontario: London, CA

2005-01-01 to present | Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function (Schulich School of Medicine & Dentistry)

Employment

Robert Hegele

https://orcid.org/0000-0003-2861-5325

Personal information

Emails & domains

Verified email domains

Other IDs

Biography

Activities

Employment (4)

University of Western Ontario: London, CA

Western University: London, CA

University of Western Ontario: London, CA

London Health Sciences Centre: London, CA

Education and qualifications (3)

Royal College of Physicians and Surgeons of Canada: Ottawa, CA

Royal College of Physicians and Surgeons of Canada: Ottawa, CA

University of Toronto: ON, ON, CA

Professional activities (3)

Montreal Clinical Research Institute: Montreal, CA

Amgen (Canada): Mississauga, CA

Aegerion Pharmaceuticals (United States): Cambridge, US

Funding (3)

Clinical translation of genomic determinants of dyslipidemia

Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function

Clinical translation of genomic understanding of cardiometabolic risk

Works (50 of 114)

Comparison of Patients With Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia Syndrome

Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia

Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America

Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia

Molecular Therapeutics in Development to Treat Hyperlipoproteinemia

Lipoprotein Lipase: Structure, Function, and Genetic Variation

Differential effects of volanesorsen on apoC-III, triglycerides and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or nongenetic criteria

Lipoprotein Lipase: Structure, Function, and Genetic Variation

Dysbetalipoproteinemia: Focus on a Neglected Lipid Disorder

The Emerging Potential of Apolipoprotein C-III Inhibition for ASCVD Prevention: A State-of-the-Art Review.

Reduced lipoprotein (a) in patients with severe hypertriglyceridaemia

Phenotype in Individuals with Heterozygous Rare Variants in LIPC Encoding Hepatic Lipase

Rapid DNA Diagnosis of Familial Hypercholesterolemia Due to the LDLR 15.8-Kilobase Deletion

Elderly patients with very high plasma lipoprotein(a) concentrations and few cardiovascular consequences: a case series

What Guidelines Say About Risk Reduction: Major Data on the Link Between Lipid Lowering and Outcomes.

Influence of Polygenic Background on the Clinical Presentation of Familial Hypercholesterolemia

Time to Give Thanks and Welcome New Members to the Editorial Team

Combined Lipid Disturbances: More Than the Sum of Their Parts?

Etiology and emerging treatments for familial chylomicronemia syndrome

Benchmarking computational variant effect predictors by their ability to infer human traits.

Prevention and Management of Cardiovascular Disease in Primary Care: A Comment on the PEER Simplified Lipid Guideline.

Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies

Pancreatitis risk in genetic subtypes of multifactorial chylomicronemia syndrome

Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease.

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome

Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia

Inhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon?

Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial Hypercholesterolemia

Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia

A Century of Milestones and Breakthroughs Related to Low- and High-Density Lipoproteins

Lipoprotein(a) in Familial Hypercholesterolemia

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

New Biological Therapies for Low-Density Lipoprotein Cholesterol

Illuminating the full spectrum of APOE variation

Polygenic risk for triglyceride levels in the presence of a high impact rare variant

Evaluation of apolipoprotein A5 variants: A cohort of patients with severe hypertriglyceridemia from Turkiye

Variability of longitudinal triglyceride phenotype in patients heterozygous for pathogenic APOA5 variants

Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies

Genetic testing in monogenic early-onset atrial fibrillation

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

Apolipoprotein C-II: a new look at an old protein

Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors

Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management

Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia

Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab

Low cholesterol states: clinical implications and management

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada

Genetic Identification of Homozygous Familial Hypercholesterolemia by Long-Read Sequencing Among Patients With Clinically Diagnosed Heterozygous Familial Hypercholesterolemia

DNA testing in dyslipidemia: attitudes and complexities.

How reliable are polygenic risk scores for risk prediction in patients with heart disease?

Peer review (139 reviews for 32 publications/grants)